论文部分内容阅读
[目的]观察艾迪注射液联合化疗治疗晚期卵巢癌的临床疗效。[方法]将60例晚期卵巢癌患者随机分为治疗组30例和对照组30例,对照组接受单纯化疗,治疗组在化疗基础上用艾迪注射液治疗,21d为1个周期,2个周期后比较两组的临床疗效。[结果]艾迪注射液具有增加化疗疗效,提高化疗患者生存质量及增加患者体重等作用,与对照组有显著性差异(P<0.05)。[结论]艾迪注射液联合化疗在晚期卵巢癌治疗中有较好疗效,值得临床进一步推广使用。
[Objective] To observe the clinical efficacy of Aidi Injection combined with chemotherapy in the treatment of advanced ovarian cancer. [Methods] Sixty patients with advanced ovarian cancer were randomly divided into treatment group (n = 30) and control group (n = 30). The control group received chemotherapy alone. The treatment group was treated with Aidi Injection on the basis of chemotherapy. After comparing the clinical efficacy of the two groups. [Results] Aidi injection had the effects of increasing the curative effect of chemotherapy, improving the quality of life of chemotherapy patients and increasing the weight of patients, which was significantly different from the control group (P <0.05). [Conclusion] Aidi injection combined with chemotherapy has a good curative effect in the treatment of advanced ovarian cancer and is worth further promotion and use in clinic.